This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Healthy Volunteers
and you are
between 18 and 55
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formulation. The effect of food on apremilast oral suspension will also be evaluated. In addition, information on the safety and tolerability of apremilast will be obtained. CC-10004 (also known as apremilast or Otezla®) has been approved by the Food and Drug Administration (FDA) for the treatment of active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis in adults. The liquid formulation of apremilast is an investigational drug being developed by Celgene Corporation to treat plaque psoriasis in children. An investigational drug is not approved by the U.S. Food and Drug Administration (FDA).

Provided treatments

  • Drug: Apremilast
  • Drug: Apremilast Oral Suspension

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02641353. The sponsor of the trial is Amgen and it is looking for 34 volunteers for the current phase.
Official trial title:
A Phase 1, Open-Label, Randomized Three-Period, Six-Sequence Crossover Study In Healthy Adult Subjects To Evaluate The Bioavailablity Of An Oral Suspension Formulation Relative To The Tablet Formulation Of Apremilast And To Assess The Effect Of Food On The Pharmacokinetics Of The Oral Suspension Formulation